Ann: Half Yearly Report and Accounts, page-2

Revenue was $377,181 (2022: $1,220,101) as in the prior year there were one off device revenues of $747,827 relating toclinical studies. The shift in focus towards commercialisation activities, targeting the USA market has led to a reduction inclinical studies revenue for the current period and associated device sales. However, the channel partner investments,recruitment of business development staff in the USA during the year and commercial agreements signed with largemedical groups with RPM reimbursements is starting to materialise and is expected to grow revenue in the second halfof the financial year.

targeting the USA market has led to a reduction inclinical studies revenue for the current period and associated device sales.

CM has been calling this for some time now, so at least that side of things has changed due to concentrating on the US.